ArticleBMC chemistry2026
In vitro and in silico characterization of Crocatin A from red betel leaves: targeting DNA gyrase B and DNA ligase of Enterococcus faecalis with ADMET-based druglikeness analysis.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dental caries is a disease of tooth tissue that can lead to complications, with Enterococcus faecalis being one of the Gram-positive bacteria that plays a crucial role in the infection process. Red betel leaves (Piper crocatum Ruiz & Pav.) are known to contain various phytochemicals; however, the antibacterial potential of Crocatin A, one of its isolated compounds, against E. faecalis and its molecular targets has not been previously reported. This study hypothesized that Crocatin A exhibits antibacterial activity against E. faecalis and has the potential to inhibit DNA gyrase B and DNA ligase, which are essential enzymes in DNA replication. Crocatin A was isolated from P. crocatum via column chromatography and characterized using infrared (IR) spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry. In vitro assays were carried out using the Kirby-Bauer disk diffusion method at concentrations of 1, 2, and 5%, as well as the microdilution method. Antibacterial activity was further analyzed in silico to predict binding affinity toward DNA gyrase B and DNA ligase, along with the evaluation of ADMET properties. The results demonstrated that Crocatin A produced concentration-dependent inhibition zones and exhibited a minimum inhibitory concentration (MIC) of 1250 µg/mL. In silico studies revealed binding energies of -6.34 kcal/mol for DNA gyrase B and - 5.77 kcal/mol for DNA ligase. In summary, Crocatin A showed moderate inhibition zones in vitro, although its MIC and MBC activities remain weak. In silico screening suggested possible binding interactions with DNA gyrase B and DNA ligase. Given the preliminary nature of these findings and the methodological limitations of the study, further validation is required to confirm its antibacterial potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.